In a 41-year-old male with a 15–20-year history of heavy alcohol consumption (approximately 500 mL per day), who has completed a 7‑day binge and experienced recent vomiting but has normal oxygen saturation, normal heart rate, and normal blood pressure, what is the appropriate alcohol withdrawal and abstinence protocol?

Alcohol Abstinence Protocol

This patient requires immediate assessment for alcohol withdrawal syndrome (AWS) using the CIWA-Ar scale, followed by benzodiazepine-based pharmacological management if moderate-to-severe withdrawal is present (CIWA-Ar >8), combined with thiamine supplementation and supportive care, then transition to long-term abstinence maintenance therapy with naltrexone or acamprosate plus counseling.

Immediate Management: Alcohol Withdrawal Syndrome

Assessment and Risk Stratification

Given this patient's 15-20 year history of heavy drinking (500 mL/day) with recent 7-day binge and vomiting, he is at significant risk for AWS despite currently stable vital signs. AWS typically develops within 6-24 hours after the last drink and can progress from mild symptoms (tremors, anxiety, nausea, vomiting) to severe complications including seizures, delirium tremens, cardiac arrest, and death 1.

Use the CIWA-Ar (Clinical Institute Withdrawal Assessment for Alcohol) scale to objectively assess withdrawal severity:

• CIWA-Ar score >8 indicates moderate AWS requiring pharmacological treatment
• CIWA-Ar score ≥15 indicates severe AWS 1

Critical Clinical Evaluation

Assess for factors requiring inpatient admission 2:

• Significant AWS symptoms
• History of withdrawal seizures or delirium tremens
• Serious medical comorbidities (given his low BMI of 16.6 kg/m² - weight 48 kg, height 170 cm - malnutrition is likely)
• Psychiatric comorbidities
• Lack of adequate social support

Given his severe malnutrition (BMI 16.6), history of vomiting, and chronic heavy alcohol use, strongly consider hospital admission for monitored withdrawal management.

Pharmacological Treatment for AWS

Benzodiazepines are the gold standard treatment 1, 2:

For this patient without known liver dysfunction, use long-acting benzodiazepines for better seizure and delirium prevention:

• Chlordiazepoxide: 25-100 mg PO every 4-6 hours 2
• Diazepam: 5-10 mg PO/IV every 6-8 hours 2

Use symptom-triggered regimen rather than fixed-dose schedule to prevent drug accumulation 1. Administer benzodiazepines based on CIWA-Ar scores with reassessment every 1-2 hours initially.

Important caveat: If liver function tests reveal hepatic dysfunction (which should be checked given his chronic alcohol use and malnutrition), switch to intermediate-acting benzodiazepines:

• Lorazepam: 1-4 mg PO/IV/IM every 4-8 hours 2
• Lorazepam is safer in hepatic dysfunction as it undergoes direct glucuronidation

Duration: Limit benzodiazepine use to 10-14 days maximum due to abuse potential, especially in patients with alcohol use disorder 1.

Essential Supportive Care

Thiamine supplementation is mandatory 2:

• Thiamine 100-300 mg/day for prevention of Wernicke encephalopathy
• Must be given before any IV glucose administration
• Continue for 2-3 months after withdrawal resolution
• Given his malnutrition and vomiting, consider higher doses (100-500 mg/day) initially

Additional supportive measures:

• IV fluids for hydration (he has had vomiting)
• Electrolyte correction, especially magnesium (commonly depleted in chronic alcoholism)
• Multivitamin supplementation
• Nutritional support given severe malnutrition

Monitoring Protocol

Daily monitoring for up to 5 days after last drink 3:

• Vital signs every 4-6 hours initially
• CIWA-Ar scores every 1-2 hours until stable, then every 4-6 hours
• Watch for progression to severe withdrawal, seizures, or delirium tremens
• Assess for concurrent medical complications (pancreatitis, GI bleeding, infection)

Long-Term Abstinence Maintenance

Transition to Pharmacotherapy for Alcohol Use Disorder

Once detoxification is complete and patient is abstinent, initiate maintenance therapy 4:

First-line options (Class I, Level A evidence):

1. Naltrexone 50 mg PO daily - reduces craving and prevents relapse to heavy drinking 4

   • Caution: Can cause hepatocellular injury; check liver function tests first
   • Contraindicated if significant liver disease present
   • More effective for preventing relapse to heavy drinking

2. Acamprosate 666 mg PO three times daily - reduces withdrawal symptoms and craving 4

   • More effective for maintaining abstinence once achieved
   • Safer in liver disease
   • Must be used in combination with counseling
   • Best for patients already detoxified and abstinent

Second-line option for this specific patient:

Given his likely liver disease (chronic heavy alcohol use, malnutrition, low BMI), consider Baclofen as an alternative:

• Only medication tested in patients with cirrhosis and alcohol use disorder 1, 4
• Demonstrated safety and efficacy in promoting abstinence in patients with advanced liver disease
• GABA-B receptor agonist
• Can be used for both AWS management and long-term abstinence maintenance

Avoid disulfiram in this patient due to:

• Poor tolerability
• Risk of hepatotoxicity, especially concerning given his likely underlying liver disease 4
• Limited evidence for effectiveness

Essential Psychosocial Component

Pharmacotherapy must be combined with counseling 4:

• Brief motivational interviewing (15-minute sessions with feedback, advice, goal-setting)
• Cognitive behavioral therapy enhances outcomes when combined with pharmacotherapy
• Refer to peer support programs (Alcoholics Anonymous, SMART Recovery) - Level A evidence for maintaining abstinence 5
• Psychiatric consultation recommended for comprehensive evaluation and long-term planning 2

Critical Investigations Required

Before initiating treatment, obtain:

• Complete blood count (assess for anemia, thrombocytopenia)
• Comprehensive metabolic panel (electrolytes, renal function, glucose)
• Liver function tests (AST, ALT, bilirubin, albumin, INR) - essential for medication selection
• Magnesium, phosphate levels
• Blood alcohol level
• Consider AUDIT questionnaire score to assess severity of alcohol use disorder 1

Given his severe malnutrition and chronic alcohol use, also consider:

• Abdominal ultrasound or CT to assess for liver disease, pancreatitis
• Upper GI evaluation if vomiting persists
• Screening for alcohol-related complications (cardiomyopathy, neuropathy)

Common Pitfalls to Avoid

1. Underestimating withdrawal risk - Normal vital signs now do not exclude impending severe withdrawal; symptoms can progress over 24-72 hours
2. Forgetting thiamine before glucose - Can precipitate acute Wernicke encephalopathy
3. Using naltrexone in liver disease - Check liver function first; use acamprosate or baclofen if cirrhosis present
4. Prolonged benzodiazepine use - Limit to 10-14 days to prevent dependence
5. Inadequate nutritional assessment - His BMI of 16.6 indicates severe malnutrition requiring aggressive nutritional support
6. Starting maintenance therapy too early - Acamprosate and naltrexone work best after detoxification is complete
7. Pharmacotherapy without counseling - Combined approach significantly more effective than either alone

Prognosis and Follow-up

Recidivism rates are high (67-81% over 1 year) 4, making long-term follow-up essential:

• Weekly visits initially, then monthly
• Monitor for relapse, medication adherence, side effects
• Reassess with AUDIT periodically
• Address any psychiatric comorbidities (anxiety, depression common in alcohol use disorder)
• Strict lifelong abstinence is the goal - no safe level of alcohol consumption after alcohol use disorder 4